<
>
Upadacitinib(1310726-60-3)
Product Summary
Upadacitinib (1310726-60-3) Physical Properties Property Value Density 1.56±0.1 g/cm³ (Predicted) Storage Conditions Store at -20°C Solubility Data Solvent Maximum Concentration (mg/mL) Maximum Concentration (mM) DMSO 42.67 112.17 DMSO:PBS (pH 7.2) (1:1) 0.5 1.31 DMF 30.0 78.87 Ethanol 76.0 199.8 ...
Product Custom Attributes
CAS No.:
1310726-60-3
Molecular Formula:
C17H19F3N6O
Molecular Weight:
380.37
EINECS No.:
213-161-9
Form:
White To Off-white Crystalline Solid
Highlight:
CAS No. 1310726-60-3 Upadacitinib
,Molecular Formula C17H19F3N6O Upadacitinib
,White to off-white crystalline solid JAK1 inhibitor
Basic Properties
Brand Name:
Farmasino
Model Number:
Upadacitinib
Trading Properties
Packaging Details:
25kg/drum
Payment Terms:
L/C,T/T,Western Union
Product Description
Upadacitinib (1310726-60-3)
Physical Properties
| Property | Value |
|---|---|
| Density | 1.56±0.1 g/cm³ (Predicted) |
| Storage Conditions | Store at -20°C |
Solubility Data
| Solvent | Maximum Concentration (mg/mL) | Maximum Concentration (mM) |
|---|---|---|
| DMSO | 42.67 | 112.17 |
| DMSO:PBS (pH 7.2) (1:1) | 0.5 | 1.31 |
| DMF | 30.0 | 78.87 |
| Ethanol | 76.0 | 199.8 |
Product Overview
Upadacitinib is a selective JAK1 inhibitor that has demonstrated excellent efficacy in clinical trials for the treatment of various autoimmune and inflammatory disorders.
Clinical Efficacy
Upadacitinib has shown remarkable efficacy in clinical trials for treating autoimmune and inflammatory diseases. Developed by AbbVie, this oral small-molecule targeted drug was approved for the treatment of atopic dermatitis (AD), rheumatoid arthritis (RA), and psoriatic arthritis (PsA) in adults and adolescents aged 12 years and older. It is currently the selective JAK1 inhibitor with the most covered indications in China.
Mechanism of Action
Upadacitinib is an oral JAK1 inhibitor used for treating rheumatoid arthritis and psoriatic arthritis. JAK kinases belong to a family of non-receptor tyrosine kinases with four identified members: JAK1, JAK2, JAK3, and TYK1. The substrate of JAK is STAT (Signal Transducer and Activator of Transcription). After phosphorylation by JAK, STAT dimerizes, crosses the nuclear membrane, and enters the nucleus to regulate gene expression through the JAK-STAT pathway. This mechanism plays a crucial role in immune-mediated diseases.
Therapeutic Applications
Upadacitinib (ABT-494) is a highly potent, orally active, and selective Janus kinase 1 (JAK1) inhibitor (IC50 = 43 nM) with approximately 74-fold selectivity for JAK1 over JAK2 (200 nM). It is used in the treatment of various autoimmune diseases including atopic dermatitis, rheumatoid arthritis, psoriasis, and ulcerative colitis.
Additional Product Documentation
Contact Our Experts And Get A Free Consultation!
Our mission is to offer "High Quality" & "Good Service" & "Fast Delivery" to help our clients to gain more profits.
